Cite
Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG)
MLA
Muaiad Kittaneh, et al. “Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Metastatic Breast Cancer: A Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG).” Breast Cancer Research and Treatment, vol. 171, no. 1, Apr. 2018. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b91075d701d59362ab3acf1eb80b26f0&authtype=sso&custid=ns315887.
APA
Muaiad Kittaneh, Reshma Mahtani, Robert E. Coleman, Kevin Kalinsky, Jame Abraham, Mark D. Pegram, Anthony D. Elias, Charles L. Vogel, Elyse E. Lower, Frankie A. Holmes, & E. Terry Mamounas. (2018). Use of cyclin-dependent kinase (CDK) 4/6 inhibitors for hormone receptor-positive, human epidermal growth factor receptor 2-negative, metastatic breast cancer: a roundtable discussion by The Breast Cancer Therapy Expert Group (BCTEG). Breast Cancer Research and Treatment, 171(1).
Chicago
Muaiad Kittaneh, Reshma Mahtani, Robert E. Coleman, Kevin Kalinsky, Jame Abraham, Mark D. Pegram, Anthony D. Elias, et al. 2018. “Use of Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors for Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Metastatic Breast Cancer: A Roundtable Discussion by The Breast Cancer Therapy Expert Group (BCTEG).” Breast Cancer Research and Treatment 171 (1). http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....b91075d701d59362ab3acf1eb80b26f0&authtype=sso&custid=ns315887.